Literature DB >> 22858159

Epidemiological surveillance of myotonic dystrophy type 1: a 25-year population-based study.

Jean Mathieu1, Claude Prévost.   

Abstract

This epidemiological study investigates the evolution of the prevalence and the phenotypes in a large cohort of myotonic dystrophy type 1 (DM1) patients living in the Saguenay-Lac-Saint-Jean (SLSJ) region (Quebec, Canada) over a 25-year period (1985-2010). In 1985, 406 patients with DM1 were known. From 1985 to 2010, 352 new DM1 patients were diagnosed and 321 patients died. During this period, we observed a significant ageing of the DM1 population, from a median age of 34.5years to 49.0years. The proportion of patients with an adult phenotype decreased significantly from 78% to 53% while the proportion of patients with a mild phenotype increased from 6% to 26%. Reasons for the ageing of the DM1 population and the changes in the distribution of DM1 phenotypes include the progressive lowering of total fertility rates over the last decades, a reduction of births at risk as a result of genetic counselling and prenatal diagnosis, and an increase in the number of mildly affected patients often recognised at an older age by predictive testing and molecular analysis. Although the DM1 prevalence remains very high in 2010 (158/100,000) in the SLSJ region, we observe a trend toward a decline in point prevalence rates over the last 10years.
Copyright © 2012. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2012        PMID: 22858159     DOI: 10.1016/j.nmd.2012.05.017

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  8 in total

1.  Allele length of the DMPK CTG repeat is a predictor of progressive myotonic dystrophy type 1 phenotypes.

Authors:  Gayle Overend; Cécilia Légaré; Jean Mathieu; Luigi Bouchard; Cynthia Gagnon; Darren G Monckton
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

2.  Massively Parallel Optimization of the Linker Domain in Small Molecule Dimers Targeting a Toxic r(CUG) Repeat Expansion.

Authors:  Simon Vezina-Dawod; Alicia J Angelbello; Shruti Choudhary; Kye Won Wang; Ilyas Yildirim; Matthew D Disney
Journal:  ACS Med Chem Lett       Date:  2021-03-02       Impact factor: 4.632

3.  Comparisons of intellectual capacities between mild and classic adult-onset phenotypes of myotonic dystrophy type 1 (DM1).

Authors:  Stéphane Jean; Louis Richer; Luc Laberge; Jean Mathieu
Journal:  Orphanet J Rare Dis       Date:  2014-11-26       Impact factor: 4.123

4.  CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review.

Authors:  Haris Babačić; Aditi Mehta; Olivia Merkel; Benedikt Schoser
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 5.  Muscle wasting in myotonic dystrophies: a model of premature aging.

Authors:  Alba Judith Mateos-Aierdi; Maria Goicoechea; Ana Aiastui; Roberto Fernández-Torrón; Mikel Garcia-Puga; Ander Matheu; Adolfo López de Munain
Journal:  Front Aging Neurosci       Date:  2015-07-09       Impact factor: 5.750

Review 6.  Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy.

Authors:  Laurène M André; C Rosanne M Ausems; Derick G Wansink; Bé Wieringa
Journal:  Front Neurol       Date:  2018-05-28       Impact factor: 4.003

Review 7.  Genetic burden linked to founder effects in Saguenay-Lac-Saint-Jean illustrates the importance of genetic screening test availability.

Authors:  Mbarka Bchetnia; Luigi Bouchard; Jean Mathieu; Philippe M Campeau; Charles Morin; Diane Brisson; Anne-Marie Laberge; Hélène Vézina; Daniel Gaudet; Catherine Laprise
Journal:  J Med Genet       Date:  2021-04-28       Impact factor: 6.318

Review 8.  Targeting Myotonic Dystrophy Type 1 with Metformin.

Authors:  Mikel García-Puga; Ander Saenz-Antoñanzas; Ander Matheu; Adolfo López de Munain
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.